DEF 14A: Dermata Therapeutics Seeks Stockholder Approval for Equity Plan Amendment and Reverse Stock Split

Dermata Therapeutics is asking stockholders to approve an amendment to its equity incentive plan and a reverse stock split at its upcoming annual meeting on May 7, 2024.

Summary

• Dermata Therapeutics is holding its Annual Meeting of Stockholders on May 7, 2024, virtually.
• Stockholders of record as of March 20, 2024, are entitled to vote.
• The company is seeking approval for several proposals, including the election of three directors, an amendment to the 2021 Omnibus Equity Incentive Plan to increase the share limit to 1,198,951 and adjust the evergreen provision to 5%, and an amendment to the Certificate of Incorporation to allow for a reverse stock split at a ratio between 1:5 and 1:30.
• Additionally, stockholders will vote on ratifying the appointment of Moss Adams LLP as the independent registered public accounting firm for the year ending December 31, 2024, and approving the adjournment of the Annual Meeting if necessary.
• The Board of Directors recommends voting FOR all director nominees and FOR Proposals 2, 3, 4, and 5.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting information about the upcoming annual meeting and proposals for stockholder vote. While the reverse stock split proposal suggests potential financial challenges, the overall sentiment is balanced.

Positives

• The proposed reverse stock split aims to maintain the company's listing on Nasdaq.
• The increased share authorization under the equity incentive plan is intended to attract, retain, and motivate high-quality talent.
• The Board believes the reverse stock split could improve the marketability and liquidity of the company's common stock.

Negatives

• The reverse stock split could decrease the liquidity of the company's common stock.
• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq compliance.
• Future issuances of common stock could dilute existing stockholders' ownership.

Risks

• Failure to approve the reverse stock split could result in delisting from Nasdaq.
• The market price of the company's common stock may decrease even after implementing the reverse stock split.
• The reverse stock split may result in some stockholders owning 'odd lots' of less than 100 shares, which may be more difficult to sell.

Future Outlook

The company is seeking to maintain its Nasdaq listing and improve its ability to attract and retain talent through the proposed actions.

Management Comments

• The Board believes that the election of the director nominees, the Plan Amendment Proposal, the Reverse Split Proposal, the Auditor Proposal, and the Adjournment Proposal are advisable and in the best interests of the Company and its stockholders.

Industry Context

The document highlights the importance of equity-based compensation in the biopharmaceutical industry for attracting and retaining talent, and the need to maintain a Nasdaq listing to improve marketability and liquidity.

Comparison to Industry Standards

• The Board reviewed market, industry and compensation peer group practices and data in determining the number of additional shares to be reserved for issued under the 2021 Plan and the appropriate evergreen percentage under the amended 2021 Plan.
• The Board determined that the 2021 Plan does not provide sufficient share authorization to appropriately compensate our employees, non-employee directors and consultants for a duration comparable to that of the equity incentive plans of similarly situated companies.

Related Party Transactions

• Sean Proehl, the son of Gerald T. Proehl, our Chief Executive Officer, is currently employed as our Associate General Counsel and receives a salary of $200,000 a year.

Stakeholder Impact

• Stockholders will be impacted by the reverse stock split and potential dilution from future share issuances.
• Employees and directors may be impacted by changes to the equity incentive plan.
• The company's ability to attract and retain talent could be affected by the approval of the equity incentive plan amendment.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on May 7, 2024.
• The Board will determine the specific ratio for the reverse stock split if approved.
• The company will file the Reverse Split Charter Amendment with the Secretary of State of the State of Delaware if the reverse stock split is approved and the Board elects to implement it.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, equity incentive plan, director election, Moss Adams, Dermata Therapeutics, stockholders